Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
Gertsik L, Poland RE, Bresee C, Rapaport MH
Journal of clinical psychopharmacology · 119 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- National Institute on Minority Health and Health Disparities
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NCRR NIH HHS
- Gobierno
- NCATS NIH HHS
- Gobierno
- NIMHD NIH HHS
- Gobierno
- NCCIH NIH HHS
- Subvenciones
- National Institute on Minority Health and Health Disparities (U54 MD-007593); National Center for Complementary and Integrative Health (R21 AT001077); National Institutes of Health (UL1TR000124); National Center for Research Resources (M01RR000425); National Center for Research Resources (U54 RR026140)
Según 9 financiadores declarados.
Publicación
- Publicado
- 2011-12-24 · J Clin Psychopharmacol · vol. 32 · número 1 · págs. 61–64
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 162 citas · más que el 98% de estudios similares · 8.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 38 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Treatment of Major Depression · Tryptophan and brain disorders
- Palabras clave
- omega-3 fatty acids, citalopram, major depressive disorder, combination therapy, eicosapentaenoic acid, docosahexaenoic acid, selective serotonin reuptake inhibitors, antidepressant response, olive oil placebo
- MeSH
- humans, citalopram, fatty acids, omega-3, antidepressive agents, second-generation, treatment outcome, drug therapy, combination, dietary supplements, adult, middle aged, female, male, major depressive disorder
4 autores
- Lev Gertsik🇺🇸 · autor de correspondenciaCedars-Sinai Medical Center
- Russell E. Poland🇺🇸Meharry Medical College; Cedars-Sinai Medical Center
- Catherine J. Bresee🇺🇸Cedars-Sinai Medical Center
- Mark Hyman Rapaport🇺🇸Cedars-Sinai Medical Center; University of California, Los Angeles
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with major depressive disorder (MDD). We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response.
Methods
Forty-two subjects participated in this 9-week randomized, masked, placebo-controlled study of combination therapy (two 1 g capsules containing a blend of 900 mg of eicosapentaenoic acid, 200 mg of and docosahexaenoic acid, and 100 mg of other omega-3 fatty acids twice daily plus citalopram) versus monotherapy (two 1 g capsules of olive oil per day plus citalopram) treatment of MDD.
Results
The combination therapy demonstrated significantly greater improvement in Hamilton Depression Rating scale scores over time (F = 7.32; df 1,177; P = 0.008) beginning at week 4 (t = -2.48; df 177; P = 0.014).
Conclusions
Combination therapy was more effective than monotherapy in decreasing signs and symptoms of MDD during the 8 weeks of active treatment; however, combination therapy did not seem to enhance the speed of the initial antidepressant response. These findings suggest that there may be an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with MDD. A larger definitive study is warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.